Last reviewed · How we verify
Edaravone Dexborneol — Competitive Intelligence Brief
marketed
Free radical scavenger combination
Neurology
Small molecule
Live · refreshed every 30 min
Target snapshot
Edaravone Dexborneol (Edaravone Dexborneol) — First Affiliated Hospital, Sun Yat-Sen University. Edaravone Dexborneol is a combination of a free radical scavenger and a borneol-based neuroprotective agent that reduces oxidative stress and improves cerebral blood flow.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Edaravone Dexborneol TARGET | Edaravone Dexborneol | First Affiliated Hospital, Sun Yat-Sen University | marketed | Free radical scavenger combination |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Free radical scavenger combination class)
- First Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Edaravone Dexborneol CI watch — RSS
- Edaravone Dexborneol CI watch — Atom
- Edaravone Dexborneol CI watch — JSON
- Edaravone Dexborneol alone — RSS
- Whole Free radical scavenger combination class — RSS
Cite this brief
Drug Landscape (2026). Edaravone Dexborneol — Competitive Intelligence Brief. https://druglandscape.com/ci/edaravone-dexborneol. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab